Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Thursday, July 2, 2009

Sepracor depression drug disappoints in trial

By Craig M. Douglas

Drug maker Sepracor Inc. said it is determining whether to continue the development of its most advanced candidate for the treatment of depression after a Phase 2 clinical trial returned “inconclusive” results that fell short of the company’s initial goals.

Sepracor, based in Marlborough, said the 514-person study was designed to evaluate the safety and effectiveness of its drug candidate, identified as SEP-225289, for the treatment of major depressive disorder. The company said the drug failed to result in a reduction in symptoms of depression following eight weeks of treatment. In a regulatory filing late Wednesday, Sepracor (Nasdaq: SEPR) said it is “in the process of further analysis of the dose response and secondary endpoints to determine how or if it will move forward with SEP-225289.”

Sepracor reported a profit of $515 million for fiscal 2008, on revenue of $1.3 billion.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Tech Pulse Poll

What's your level of interest in Pinterest?



View Results

Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement and Privacy Policy. About our ads.